Long-Term Results of Amitriptyline Treatment for Interstitial Cystitis

Abstract

Purpose: We have conducted a prospective open-label study to examine the safety and efficacy of the long-term administration of the tricyclic antidepressant amitriptyline in patients with interstitial cystitis (IC). Methods: Patients were stratified into 2 groups: an NIDDK group including patients fulfilling the NIDDK criteria for IC and a non-NIDDK group encompassing patients who presented the characteristic IC symptoms but met at least one of the NIDDK exclusion criteria. Amitriptyline was taken strictly at bedtime following an established self-titration protocol without a limitation of the ­maximum daily dosage. Patients reporting improvement in a global response assessment questionnaire were defined as treatment responders. Further efficacy measures included changes of pain and urgency, functional bladder capacity and frequency. Changes in the O’Leary-Sant IC ­index and rating of overall satisfaction with the therapeutic outcome are reported as well. Results: The mean follow-up of the study was 19.0 ± 12.5 months. The response rate was 64 % (60 patients). Overall mean dosage was 55 mg (range: 12.5–150 mg). Side effects occurred in 79 patients (84 %) (dry mouth: 79 %, weight gain: 59 %). Patient overall satisfaction with the therapeutic result was either excellent or good in 43 patients (46 %). The drop-out rate was 31 % (29 patients) after a mean treatment period of 6 weeks at a mean dosage of 70 mg. Non-response to treatment was the primary reason for drop-out in all cases, side effects contributed to drop-out in 25 patients (86 %). The various IC symptoms improved statistically significant compared with baseline. Conclusions: Long-term administration of amitriptyline is a feasible, safe and effective treatment for IC provided that the drug is used ­judiciously to minimise adverse effects. The therapeutic response to amitriptyline was uniformly observed in patients fulfilling the NIDDK criteria and in those patients with the pure clinical diagnosis of IC.

amitryptiline - interstitial cystitis - bladder

References

• 1 van Ophoven A, Pokupic S, Heinecke A et al. A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis.  J Urol. 2004;  172 533-536
• 2 Nordling J, Anjum F H, Bade J J et al. Primary evaluation of patients ­suspected of having interstitial cystitis (IC).  Eur Urol. 2004;  45 662-669
• 3 Hanno P M, Landis J R, Matthews-Cook Y et al. The diagnosis of interstitial cystitis revisited: lessons learned from the National Institutes of Health Interstitial Cystitis Database study.  Journal of Urology. 1999;  161 553-557
• 4 O’Leary M P, Sant G R, Fowler Jr F J et al. The interstitial cystitis symptom index and problem index.  Urology. 1997;  49 (5 A Suppl) 58-63
• 5 NIH Common Toxicity Criteria. Available at http://www.fda.gov/cder/cancer/toxicityframe.htm. Accessed 01–17–2005
• 6 Gantz S A. Primer of Biostatistics. 4th edn. New York: McGraw-Hill; 1997
• 7 Gillenwater J Y, Wein A J. Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cys­titis, National Institutes of Health, Bethesda, Maryland, August 28–29, 1987.  Journal of Urology. 1988;  140 203-206
• 8 Nordling J. Interstitial cystitis: how should we diagnose it and treat it in 2004?.  Curr Opin Urol. 2004;  14 323-327
• 9 Keay S K, Szekely Z, Conrads T P et al. An antiproliferative factor from interstitial cystitis patients is a frizzled 8 protein-related sialoglycopeptide.  Proc Natl Acad Sci USA. 2004;  101 11803-11808
• 10 Peeker R, Fall M. Toward a precise definition of interstitial cystitis: further evidence of differences in classic and nonulcer disease.  J Urol. 2002;  167 2470-2472
• 11 Sant G R, Hanno P M. Interstitial cystitis: current issues and controversies in diagnosis.  Urology. 2001;  57 (6 Suppl 1) 82-88
• 12 Erickson D R. Glomerulations in women with urethral sphincter deficiency: report of 2 cases [corrected] [published erratum appears in J Urol 1995 Jun; 153(6): 1955].  Journal of Urology. 1995;  153 (3 Pt 1) 728-729
• 13 Waxman J A, Sulak P J, Kuehl T J. Cystoscopic findings consistent with ­interstitial cystitis in normal women undergoing tubal ligation.  J Urol. 1998;  160 1663-1667
• 14 Ito T, Tomoe H, Ueda T et al. Clinical symptoms scale for interstitial cystitis for diagnosis and for following the course of the disease.  Int J Urol. 2003;  10 Suppl 24-26
• 15 Payne C K, Terai A, Komatsu K. Research criteria versus clinical criteria for interstitial cystitis.  Int J Urol. 2003;  10 Suppl 7-10
• 16 Bryson H M, Wilde M I. Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states.  Drugs Aging. 1996;  8 459-476
• 17 Guaiana G, Barbui C, Hotopf M. Amitriptyline versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev (2), CD004186. 2003
• 18 Theoharides T C, Sant G R. New agents for the medical treatment of interstitial cystitis.  Expert Opin Investig Drugs. 2001;  10 521-546
• 19 Hanno P M, Buehler J, Wein A J. Use of amitriptyline in the treatment of interstitial cystitis.  Journal of Urology. 1989;  141 846-848
• 20 Hanno P M, Wein A J. Medical treatment of interstitial cystitis (other than Rimso-50 / Elmiron).  Urology. 1987;  29 (4 Suppl) 22-26